Expert Ratings For Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:
Morgan Stanley Initiates Coverage On Arvinas with Equal-Weight Rating, Announces Price Target of $65
Morgan Stanley analyst Terence Flynn initiates coverage on Arvinas (NASDAQ:ARVN) with a Equal-Weight rating and announces Price Target of $65.
Stifel Maintains Buy on Arvinas, Lowers Price Target to $93
Stifel analyst Bradley Canino maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $100 to $93.
Where Arvinas Stands With Analysts
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:
3 Stocks To Double Down On In 2022
The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination of the omicron fears, and the anticipation of the Fed raising rates to curb the surge of inflation.
Arvinas Highlights New Data From Completed Phase 1 Dose Escalation, Ongoing Phase 2 ARDENT Cohort Will Be Presented At American Society of Clinical Oncology Genitourinary Cancers Symposium Feb. 17
– Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations –
– Arvinas plans to
Wells Fargo Initiates Coverage On Arvinas with Overweight Rating, Announces Price Target of $98
Wells Fargo analyst Derek Archila initiates coverage on Arvinas (NASDAQ:ARVN) with a Overweight rating and announces Price Target of $98.